Schizophrenia
Conditions
Keywords
NMDA, glutamate, schizophrenia
Brief summary
This study investigates the common features of electrophysiological measures in schizophrenia and effects of NMDA antagonist ketamine in healthy volunteers.
Interventions
DRUGketamine
For healthy volunteer arm of study, NMDA antagonist ketamine will be administered. 0.23 mg/kg over 1 minute, followed by 0.58 mg/kg/hour for 30 minutes, followed by 0.29 mg/kg/hour for 50 minutes. No drug administration for patients with schizophrenia
Sponsors
AstraZeneca
Yale University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
21 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
Subjects for the Ketamine experiment(Healthy control experiment): Inclusion Criteria: 1. Male or female 2. 21-45 years old 3. Deemed healthy by the Structured Clinical Interview for DSM-NP (SCID-NP) and collateral information. Subjects will need to provide the name of a person, preferably a family member, whom the research team can contact to corroborate information.
Exclusion criteria
1. Lifetime diagnosis of DSM-IV substance dependence (except caffeine and nicotine). 2. Substance abuse, as per clinical judgment, in the past 1 year. 3. Current or past DSM-IV Axis-I diagnosis. 4. A history of significant medical/neurological disease such as cardiac, thyroid, renal, hepatic or neurological. Unstable medical condition based on EKG, vital signs, physical examination and laboratory work-up. 5. A hearing deficit greater than 30 dB in both ears detected using a Welch-Allyn audioscope (500, 1000, 2000 and 4000 Hz threshold will be evaluated) at screening. 6. Major current or recent (\<6 weeks) stressors. 7. History of counseling, except if counseling was for a life circumstance disorder (e.g., bereavement, divorce) or in the opinion of the investigator, is not clinically significant. 8. Lifetime history of treatment with any psychotropic medications for \> 1 month duration suggestive of psychiatric illness. 9. Current or past Axis I diagnosis of schizophrenia or bipolar disorder in first-degree relatives. 10. Any medication that could interfere with either the safety of the study and/or the outcome measures. 11. Use of any illicit substances in the 4 weeks prior to beginning study participation. 12. Any history indicating learning disability, mental retardation, or attention deficit disorder. 13. History of head injury with loss of consciousness greater than fifteen minutes. 14. Any other condition or medication, which in the opinion of the investigator would preclude participation in the study. 15. Non-English speaking. 16. Known sensitivity to ketamine. Subjects for the Schizophrenia experiment: Inclusion Criteria for control subjects: 1. Male or female 2. 21-45 years old 3. No past or present Axis I diagnosis, as determined by the SCID-NP
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| P300, an ERP measure | Baseline and repeat assessment following ketamine |
Secondary
| Measure | Time frame |
|---|---|
| (Mismatch Negativity) MMN | Baseline and repeat assessment |
Countries
United States
Outcome results
None listed